Cancer vaccines

Journal of Clinical Oncology

Volumn 17, Issue 3, 1999, Pages 1047-1060

  Greten, Tim F ^a   Jaffee, Elizabeth M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BACTERIAL VACCINE; BETA CATENIN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; FREUND ADJUVANT; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GM2; GENE PRODUCT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; HLA ANTIGEN; IMMUNOGLOBULIN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN; MELANIN; MELANOMA ANTIGEN; MONOPHENOL MONOOXYGENASE; PROTEIN P53; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; VIRUS VACCINE;

ARTICLE; CLINICAL TRIAL; DENDRITIC CELL; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INTRADERMAL DRUG ADMINISTRATION; INTRALESIONAL DRUG ADMINISTRATION; LISTERIA MONOCYTOGENES; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE;

EID: 0000023712     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.3.1047     Document Type: Article

References (148)

1. Coley WB: The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases. Am J Med Sci 105:487-511, 1893
2. Hoover HJ, Surdyke M, Dangel RB, et al: Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer 55:1236-1243, 1985
3. Hoover HJ, Brandhorst JS, Peters LC, et al: Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-Year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 11:390-399, 1993
4. Berd D, Maguire HCJ, McCue P, et al: Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients. J Clin Oncol 8:1858-1867, 1990
5. Lipton A, Harvey HA, Balch CM, et al: Corynebacterium parvum versus Bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma. J Clin Oncol 9:1151-1156, 1991
6. McCune CS, O'Donnell RW, Marquis DM, et al: Renal cell carcinoma treated by vaccines for active specific immunotherapy: Correlation of survival with skin testing by autologous tumor cell -Bacillus Calmette-Guérin vaccine. Cancer Immunol Immunother 32:62-66, 1990
7. Pardoll DM: Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 13:399-415, 1995
8. Dranoff G, Jaffee E, Lazenby A, et al: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90:3539-3543, 1993
9. Golumbek PT, Lazenby AJ, Levitsky HI, et al: Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713-716, 1991
10. Germain RN: Immunology: The ins and outs of antigen processing and presentation. Nature 322:687-689, 1986
11. Swain SL, Bradley LM, Croft M, et al: Helper T-cell subsets: Phenotype, function and the role of lymphokines in regulating their development. Immunol Rev 123:1115-1144, 1991
12. Mackay C: Immunological memory. Adv Immunol 53:217-265, 1993
13. Boon T, Cerottini JC, Van den Eynde B; et al: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337-365, 1994
14. Jenkins MK, Schwartz RH: Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 165:302-319, 1987
15. Schwartz RH: Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71:1065-1068, 1992
16. Matzinger P: Tolerance, danger, and the extended family. Annu Rev Immunol 12:991-1045, 1994
17. Staveley-O'Carroll K, Sotomayor E, Montgomery J, et al: Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci US A95:1178-1183, 1998
18. Wick M, Dubey P, Koeppen H, et al: Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med 186:229-238, 1997
19. Speiser DE, Miranda R, Zakarian A, et al: Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy. J Exp Med 186:645-653, 1997
20. Huang AY, Golumbek P, Ahmadzadeh M, et al: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961-965, 1994
21. Albert ML, Sauter B, Bhardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class I restricted CTLs. Nature 392:86-89, 1998
22. Schoenberger SP, Toes RE, van der Voort EI, et al: T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480-483, 1998
23. Ridge JP, Di Rosa F, Matzinger P: A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393:474-478, 1998
24. Bennett SR, Carbone FR, Karamalis F, et al: Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478-480, 1998
25. Thomas MC, Greten TF, Pardoll DM, et al: Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum Gene Ther 9:835-843, 1998
26. Toes RE, Blom RJ, van Voort E, et al: Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res 56:3782-3787, 1996
27. De Plaen E, Lurquin C, Van Pel A, et al: Immunogenic (tum-) variants of mouse tumor P815: Cloning of the gene of turn-antigen P91A and identification of the turn- mutation. Proc Natl Acad Sci U S A 85:2274-2278, 1988
28. Lurquin C, Van Pel A, Mariame B, et al: Structure of the gene of tum- transplantation antigen P91 A: The mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 58:293-303, 1989
29. Vandeneynde BJ, Vanderbruggen P: T cell defined tumor antigens. Curr Opin Immunol 9:684-693, 1997
30. Cox AL, Skipper J, Chen Y, et al: Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716-719, 1994
31. Huang AYC, Gulden PH, Woods AS, et al: The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci U S A 93:9730-9735, 1996
32. Mandelboim O, Berke G, Fridkin M, et al: CTL induction by a tumor-associated antigen octapeptide derived from a murine lung carcinoma. Nature 369:67-71, 1994
33. Sahin U, Tureci O, Schmitt H, et al: Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 92:11810-11813, 1995
34. Sahin U, Tureci O, Pfreundschuh M: Serological identification of human tumor antigens. Curr Opin Immunol 9:709-716, 1997
35. Jager E, Chen YT, Drijfhout JW, et al: Simultaneous humoral and cellular immune response against cancer-testis antigen Ny-Eso-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187:265-270, 1998
36. Chen YT, Scanlan MJ, Sahin U, et al: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 94:1914-1918, 1997
37. Chen YT, Cure AO, Tsang S, et al: Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci U S A 95:6919-6923, 1998
38. Monach PA, Meredith SC, Siegel CT, et al: A unique tumor antigen produced by a single amino acid substitution. Immunity 2:45-59, 1995
39. Brichard V, Van Pel A, Wolfel T, et al: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178:489-495, 1993
40. Coulie PG, Brichard V, Van Pel A, et al: A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 180:35-42, 1994
41. Kawakami Y, Eliyahu S, Delgado CH, et al: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 91:3515-3519, 1994
42. Bakker AB, Schreurs MW, de Boer AJ, et al: Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 179:1005-1009, 1994
43. Wang RF, Robbins PF, Kawakami Y, et al: Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes [published erratum appears in J Exp Med 181:1261, 1995]. J Exp Med 181:799-804, 1995
44. Wang RF, Appella E, Kawakami Y, et al: Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 184:2207-2216, 1996
45. Wolfel T, Van Pel A, Brichard V, et al: Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 24:759-764, 1994
46. Bakker AB, Schreurs MW, Tafazzul G, et al: Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1- restricted anti-melanoma CTL line. Int J Cancer 62:97-102, 1995
47. Van der Bruggen P, Traversari C, Chomez P, et al: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1647, 1991
48. Boel P, Wildmann C, Sensi ML, et al: BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2:167-175, 1995
49. Van den Eynde B, Peeters O, De Backer O, et al: A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 182:689-698, 1995
50. Wolfel T, Hauer M, Schneider J, et al: A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281-1284, 1995
51. Peace DJ, Chen W, Nelson H, et al: T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes. J Immunol 146:2059-2065, 1991
52. Jung S, Schluesener HJ: Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J Exp Med 173:273-276, 1991
53. Fuchs EJ, Bedi A, Jones RJ, et al: Cytotoxic T cells overcome BCR-ABL-mediated resistance to apoptosis. Cancer Res 55:463-469, 1995
54. Theobald M, Biggs J, Dittmer D, et al: Targeting p53 as a general tumor antigen. Proc Natl Acad Sci U S A 92:11993-11997, 1995
55. Ambinder RF, Robertson KD, Moore SM, et al: Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma. Semin Cancer Biol 7:217-226, 1996
56. Wu TC: Immunology of the human papilloma virus in relation to cancer. Curr Opin Immunol 6:746-754, 1994
57. Chang MH, Chen CJ, Lai MS, et al: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children: Taiwan Childhood Hepatoma Study Group. N Engl J Med 336:1855-1859, 1997
58. Topalian SL, Rivoltini L, Mancini M, et al: Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 91:9461-9465, 1994
59. Azuma M, Ito D, Yagita H, et al: B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366:76-79, 1993
60. Freeman GJ, Borriello F, Hodes RJ, et al: Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 262:907-909, 1993
61. Freeman GJ, Gribben JG, Boussiotis VA, et al: Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262:909-911, 1993
62. Linsley PS, Brady W, Urnes M, et al: CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174:561-569, 1991
63. Chen L, Ashe S, Brady WA, et al: Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093-1102, 1992
64. Baskar S, Ostrand-Rosenberg S, Nabavi N, et al: Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci U S A 90:5687-5690, 1993
65. Townsend SE, Allison JP: Tumor rejection after direct costimulation of CD8+ T cells by B7- transfected melanoma cells [see comments]. Science 259:368-370, 1993
66. Cayeux S, Beck C, Dorken B, et al: Coexpression of interleukin-4 and B7.1 in murine tumor cells leads to improved tumor rejection and vaccine effect compared to single gene transfectants and a classical adjuvant. Hum Gene Ther 7:525-529, 1996
67. Cayeux S, Beck C, Aicher A, et al: Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur J Immunol 25:2325-2331, 1995
68. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 392:245-252, 1998
69. Kitamura K, Livingston PO, Fortunato SR, et al: Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine. Proc Natl Acad Sci U S A 92:2805-2809, 1995
70. Helling F, Zhang S, Shang A, et al: GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 55:2783-2788, 1995
71. Hsu FJ, Caspar CB, Czerwinski D, et al: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: Long-term results of a clinical trial. Blood 89:3129-3135, 1997
72. Ruiz JP, Wolkowicz R, Waisman A, et al: Idiotypic immunization induces immunity to mutated p53 and tumor rejection. Nat Med 4:710-712, 1998
73. Ostrand-Rosenberg S, Roby C, Clements VK, et al: Tumor-specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class-II genes or allogeneic MHC-class-I genes. Int J Cancer Suppl 6:61-68, 1991
74. Wallich R, Bulbuc N, Hammerling GJ, et al: Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315:301-305, 1985
75. Plautz GE, Yang ZY, Wu BY, et al: Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 90:4645-4649, 1993
76. Pulaski BA, McAdam AJ, Hutter EK, et al: Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism. Cancer Res 53:2112-2117, 1993
77. Gansbacher B, Zier K, Daniels B, et al: Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172:1217-1224, 1990
78. Asher M, Mule J, Kasid A: Murine tumor cells transduced with the gene for tumor necrosis factor-a. J Immunol 146:3227-3229, 1991
79. Gansbacher B, Bannerji R, Daniels B: Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 50:7820-7826, 1990
80. Hock H, Dorsch M, Diamantstein T, et al: Interleukin 7 induces CD4+ T cell-dependent tumor rejection. J Exp Med 174:1291-1298, 1991
81. Porgador A, Tzehoval E, Katz A, et al: Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 52:3679-3686, 1992
82. Blankenstein T, Qin Z, Uberla K: Tumor suppression after tumor cell-targeted tumor necrosis factor via gene transfer. J Exp Med 173:1047-1052, 1991
83. Simons JW, Jaffee EM, Weber CE, et al: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 57:1537-1546, 1997
84. Golumbek PT, Azhari R, Jaffee EM, et al: Controlled release, biodegradable cytokine depots: A new approach in cancer vaccine design. Cancer Res 53:1-4, 1993
85. Lotze MT, Zitvogel L, Campbell R, et al: Cytokine gene therapy of cancer using interleukin-12: Murine and clinical trials. Ann N Y Acad Sei 795:440-454, 1996
86. Tepper RI, Mule JJ: Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 5:153-164, 1994
87. Cheson BD, Phillips PH, Sznol M: Clinical Trials Referral Resource: Trials using tumor vaccines. Oncology 11:81-82, 84, 90, 1997
88. Arienti F, Sule-Suso J, Belli F, et al: Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum Gene Ther 7:1955-1963, 1996
89. Abdel-Wahab Z, Weltz C, Hester D, et al: A phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: Monitoring the humoral immune response. Cancer 80:401-412, 1997
90. Wolff JA, Malone RW, Williams P, et al: Direct gene transfer into mouse muscle in vivo. Science 247:1465-1468, 1990
91. Condon C, Watkins SC, Celluzzi CM, et al: DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 2:1122-1128, 1996
92. Tang DC, DeVit M, Johnston SA: Genetic immunization is a simple method for eliciting an immune response. Nature 356:152-154, 1992
93. Donnelly JJ, Ulmer JB, Shiver JW, et al: DNA vaccines. Annu Rev Immunol 15:617-648, 1997
94. Pardoll DM, Beckerleg AM: Exposing the immunology of naked DNA vaccines. Immunity 3:165-169, 1995
95. Doe B, Selby M, Barnett S, et al: Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. Proc Natl Acad Sci U S A 93:8578-8583, 1996
96. Corr M, Lee DJ, Carson DA, et al: Gene vaccination with naked plasmidDNA: Mechanism of CTL priming. J Exp Med 184:1555-1560, 1996
97. McCabe B, Irvine K, Nishimura M, et al: Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses. Cancer Res 55:1741-1757, 1995
98. Restifo NP, Bacik I, Irvine KR, et al: Antigen processing in vivo and the elicitation of primary CTL responses. J Immunol 154:4414-4422, 1995
99. Irvine K, McCabe B, Rosenberg S, et al: Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL. J Immunol 154:4651-4657, 1995
100. Wang M, Bronte V, Chen PW, et al: Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol 154:4685-4692, 1995
101. Bronte V, Tsung K, Rao JB, et al: IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol 154:5282-5292, 1995
102. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, et al: Engineer-ing an intracellular pathway for major histocompatibility complex class I! presentation of antigens. Proc Natl Acad Sci U S A 92:11671-11675, 1995
103. Lin KY, Guarnieri FG, Staveley-O'Carroll K, et al: Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56:21-26, 1996
104. Borysiewicz LK, Fiander A, Nimako M, et al: A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer [see comments]. Lancet 347:1523-1527, 1996
105. Falkow S, Isberg RR, Portnoy DA: The interaction of bacteria with mammalian cells. Annu Rev Cell Biol 8:333-363, 1992
106. Pan ZK, Ikonomidis G, Lazenby A, et al: A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nat Med 1:471-477, 1995
107. Kast WM, Offringa R, Peters PJ, et al: Eradication of adenovirus El-induced tumors by ElA-specific cytotoxic T lymphocytes. Cell 59:603-614, 1989
108. Mandelboim O, Vadai E, Fridkin M, et al: Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides [see comments]. Nat Med 1:1179-1183, 1995
109. Toes RE, Blom RJ, Offringa R, et al: Enhanced tumor outgrowth after peptide vaccination: Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol 156:3911-3918, 1996
110. Marchand M, Weynants P, Rankin E, et al: Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 63:883-885, 1995
111. Jager E, Ringhoffer M, Dienes HP, et al: Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 67:54-62, 1996
112. Parkhurst MR, Salgaller ML, Southwood S, et al: Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 157:2539-2548, 1996
113. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327, 1998
114. Tamura Y, Peng P, Liu K, et al: Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278:117-120, 1997
115. Blachere NE, Li Z, Chandawarkar RY, et al: Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med 186:1315-1322, 1997
116. Steinman RM, Cohn ZA: Identification of a novel cell type in peripheral lymphoid organs of mice: I. Morphology, quantitation, tissue distribution. J Exp Med 137:1142-1162, 1973
117. Inaba K, Inaba M, Romani N, et al: Generation of large numbers of dendritic cells from mouse bone marrow cultures supple-mented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176:1693-1702, 1992
118. Caux C, Dezutter-Dambuyant C, Schmitt D, et al: GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 360:258-261, 1992
119. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179:1109-1118, 1994
120. Romani N, Gruner S, Brang D, et al: Proliferating dendritic cell progenitors in human blood. J Exp Med 180:83-93, 1994
121. Siena S, Di Nicola M, Bregni M, et al: Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp Hematol 23:1463-1471, 1995
122. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271-296, 1991
123. Adema GJ, Hartgers F, Verstraten R, et al: A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature 387:713-717, 1997
124. Zitvogel L, Mayordomo JI, Tjandrawan T, et al: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1 -associated cytokines [see comments]. J Exp Med 183:87-97, 1996
125. Mayordomo JI, Zorina T, Storkus WJ, et al: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1:1297-1302, 1995
126. Paglia P, Chiodoni C, Rodolfo M, et al: Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317-322, 1996
127. Gong J, Chen D, Kashiwaba M, et al: Induction of antitumor activity immunization with fusion of dendritic and carcinoma cells. Nat Med 3:558-561, 1997
128. Boczkowski D, Nair SK, Snyder D, et al: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184:465-472, 1996
129. Specht JM, Wang G, Do MT, et al: Dendritic cells retrovirally transduced with a model tumor antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 186:1213-1221, 1997
130. Song W, Kong H, Carpenter H, et al: Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model tumor antigen induce protective and therapeutic antitumor immunity. J Exp Med 186:1247-1256, 1997
131. Nestle FO, Alijagic S, Gilliet M, etal: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328-332, 1998
132. Hsu FJ, Benike C, Fagnoni F, et al: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52-58, 1996
133. Gansbacher B, Houghton A, Livingston P, et al: A pilot study of immunization with HLA-A2 matched allogeneic melanoma cells that secrete interleukin-2 in patients with metastatic melanoma. Hum Gene Ther 3:677-690, 1992
134. Gansbacher B, Motzer R, Houghton A, et al: A pilot study of immunization with interleukin-2 secreting allogeneic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma. Hum Gene Ther 3:691-703, 1992
135. Osanto S, Brouwenstyn N, Vaessen N, et al: Immunization with interleukin-2 transfected melanoma cells: A phase l-II study in patients with metastatic melanoma. Hum Gene Ther 4:323-330, 1993
136. Nabel GJ, Nabel EG, Yang ZY, et al: A direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A 90:11307-11311, 1993
137. Lotze MT, Rubin JT, Carty S, et al: Gene therapy of cancer: A pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. Hum Gene Ther 5:41 -55, 1994
138. Cascinelli N, Foa R, Parmiani G, et al: Active immunization of metastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells. Hum Gene Ther 5:1059-1064, 1994
139. Sobol RE, Royston I, Fakhrai H, et al: Injection of colon carcinoma patients with autologous irradiated tumor cells and fibro-blasts genetically modified to secrete interleukin-2 (IL-2): A phase I study. Hum Gene Ther 6:195-204, 1995
140. Cassileth PA, Podack E, Sridhar K, et al: Phase I study of transfected cancer cells expressing the interleukin-2 gene product in limited stage small cell lung cancer. Hum Gene Ther 6:369-383, 1995
141. Mackiewicz A, Gomy A, Laciak M, et al: Gene therapy of human melanoma: Immunization of patients with autologous tumor cells admixed with allogeneic melanoma cells secreting interleukin 6 and soluble interleukin 6 receptor. Hum Gene Ther 6:805-811, 1995
142. Sobol RE, Fakhrai H, Shawler D, et al: Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther 2:164-167, 1995
143. Seigler HF, Darrow TL, Abdel-Wahab Z, et al: A phase I trial of human gamma interferon transduced autologous tumor cells in patients with disseminated malignant melanoma. Hum Gene Ther 5:761-777, 1994
144. Stingl G, Brocker EB, Mertelsmann R, et al: Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene. Hum Gene Ther 7:551-563, 1996
145. Belli F, Arienti F, Sule-Suso J, et al: Active immunization of metastatic melanoma patients with interleukin-2 transduced allogeneic melanoma cells: Evaluation of efficacy and tolerability. Cancer Immunol Immunother 44:197-203, 1997
146. Dranoff G, Soiffer R, Lynch T, et al: A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. Hum Gene Ther 8:111-123, 1997
147. Ellem KA, O'Rourke MG, Johnson GR, et al: A case report: Immune responses and clinical course of the first human use of granulocyte macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol Immunother 44:10-20, 1997
148. Stopeck AT, Hersh EM, Akporiaye ET, et al: Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J CHn Oncol 15:341-346, 1997